TY  - JOUR
AU  - Thierauf, Julia
AU  - Ramamurthy, Nisha
AU  - Jo, Vickie Y
AU  - Robinson, Hayley
AU  - Frazier, Ryan P
AU  - Gonzalez, Jonathan
AU  - Pacula, Maciej
AU  - Dominguez Meneses, Enrique
AU  - Nose, Vania
AU  - Nardi, Valentina
AU  - Dias-Santagata, Dora
AU  - Le, Long P
AU  - Lin, Derrick T
AU  - Faquin, William C
AU  - Wirth, Lori J
AU  - Hess, Jochen
AU  - Iafrate, A John
AU  - Lennerz, Jochen K
TI  - Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma.
JO  - The oncologist
VL  - 24
IS  - 10
SN  - 1549-490X
CY  - Hoboken, NJ
PB  - Wiley
M1  - DKFZ-2019-00885
SP  - 1356-1367
PY  - 2019
AB  - Adenoid cystic carcinoma (ACC) is an aggressive salivary gland malignancy without effective systemic therapies. Delineation of molecular profiles in ACC has led to an increased number of biomarker-stratified clinical trials; however, the clinical utility and U.S.-centric financial sustainability of integrated next-generation sequencing (NGS) in routine practice has, to our knowledge, not been assessed.In our practice, NGS genotyping was implemented at the discretion of the primary clinician. We combined NGS-based mutation and fusion detection, with MYB break-apart fluorescent in situ hybridization (FISH) and MYB immunohistochemistry. Utility was defined as the fraction of patients with tumors harboring alterations that are potentially amenable to targeted therapies. Financial sustainability was assessed using the fraction of global reimbursement.Among 181 consecutive ACC cases (2011-2018), prospective genotyping was performed in 11
LB  - PUB:(DE-HGF)16
C6  - pmid:30926674
DO  - DOI:10.1634/theoncologist.2018-0515
UR  - https://inrepo02.dkfz.de/record/143287
ER  -